NUWIQ® – Proven Efficacy
POWERFUL BLEEDING CONTROL
Prophylaxis With NUWIQ Markedly Reduced Bleeding Frequency1
In Clinical Trials of Standard Prophylaxis With NUWIQ in Adult (N=32) and Pediatric (N=59) Patients Treated for ≥6 Months1,*
Adults and Children
Median ABR for All Bleeds is 0.9
Median ABR for All Bleeds is 1.9
All Patients Experienced Fewer Bleeds with NUWIQ Prophylaxis vs On-Demand Treatment With Another FVIII Product1,2,†
Patients were switched from on-demand therapy (pre-study) with another FVIII product
to prophylaxis with NUWIQ
Prophylaxis Treatment with NUWIQ in Adults
in a study with 32 adults treated with prophylaxis for 6 months or more (median Annualized Bleed Rate (ABR) was 0.9)
Prophylaxis treatment with NUWIQ in Children
in a study with 59 children treated with prophylaxis for 6 months or more (median Annualized Bleed Rate (ABR) was 1.9)
EFFECTIVE BLEEDING RESOLUTION
On-Demand Treatment Readily Controlled Bleeding3,4
In Adults Patients Receiving On-Demand Treatment with NUWIQ
N=986 bleeds evaluated
Bleeds Resolved With 1 Infusion
With 1 or 2 Infusions
Control and Prevention of Bleeding During and After Surgery1
Thirty three surgical procedures (N=19)
In 100% of minor surgeries hemostasis rated as "excellent"
In 92% of major surgeries hemostasis rated as "excellent" or "good"
- NUWIQ full Prescribing Information. Paramus, NJ: Octapharma; rev 2021.
- Data on file. Paramus, NJ: Octapharma USA, Inc; 2015.
- Valentino LA, et al. Haemophilia.2014;20 (Suppl. 1), 1–9.
- Kessler C, et al. Haemophilia. 2015;21(Suppl. 1): 1–12.